Sorted By:

Relevance


Follow the Dollar Report

PhRMA  |  Report

Download the Executive Summary Download the Report
https://www.phrma.org/report/follow-the-dollar-report

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

PhRMA  |  Blog Post

For both groups of hospitals, the report found that charity care levels decreased in 2015 compared to 2013 and 2014.
http://catalyst.phrma.org/340b-spotlight-icymi-340b-hearing-new-reports-highlight-growing-need-for-program-reform

Milliman Report: Reducing Part D Beneficiary Costs through Point-of-Sale Rebates

PhRMA  |  Report

This report analyzes the financial impact of this kind of change, which is intended to align rebate savings with the members generating those savings.
https://www.phrma.org/report/reducing-part-d-beneficiary-costs-through-point-of-sale-rebates

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth

PhRMA  |  Blog Post

This study begs an important question: Are we doing enough to ensure the growing amount of rebates and discounts flow to the patient?
http://catalyst.phrma.org/icymi-3-new-reports-show-dramatic-slowdown-in-medicine-spending-growth

New report portrays flourishing pipeline

PhRMA  |  Blog Post

View the report, summary and graphics of the report here.  
http://catalyst.phrma.org/new-report-portrays-flourishing-pipeline

Medicines in Development for Children 2012 Report

PhRMA  |  Report

The more than 300 medicines in development listed in the new report reflect these ongoing efforts.
https://www.phrma.org/report/medicines-in-development-for-children-report

New Reports Highlight Increasing Global Competition in Biopharmaceutical R&D, Posing Significant Challenges to Future U.S. Standing

PhRMA  |  Press Release

To view the reports and related infographics, click here.
https://www.phrma.org/press-release/new-reports-highlight-increasing-global-competition-in-biopharmaceutical-randd-posing-significant-challenges-to-future-u-s-standing

Medicines in Development for Asthma 2012 Report

PhRMA  |  Report

“The good news is that potential treatments highlighted in this report offer asthma sufferers new hope of living a healthier, more productive lives.”
https://www.phrma.org/report/medicines-in-development-for-asthma-2012-report

PhRMA Statement on 2017 Special 301 Report

PhRMA  |  Press Release

PhRMA members look forward to working with USTR and other U.S. government agencies to address and resolve these and other unfair and discriminatory trade practices around the world.”
https://www.phrma.org/press-release/phrma-statement-on-2017-special-301-report

Medicines in Development for Biologics 2013 Report

PhRMA  |  Report

This report lists biologics in human clinical trials or under review by the U.S.
https://www.phrma.org/report/medicines-in-development-for-biologics-2013-report

Medicines in Development for Cancer 2015 Report

PhRMA  |  Report

In recent decades, tremendous – almost previously unthinkable – progress has been made in the fight against cancer. Advances in molecular and genomic research have revealed underlying complexities and provided insights into cancer, which we now know is actually more than 200 unique diseases. Cont...
https://www.phrma.org/report/medicines-in-development-for-cancer-2015-report

Medicines in Development for Mental Illnesses 2017 Report

PhRMA  |  Report

Biopharmaceutical research companies are developing more than 140 medicines for mental illnesses. Mental illnesses exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that nearly 18 percent of American adults and 20 percent of child...
https://www.phrma.org/report/medicines-in-development-for-mental-illnesses-2017-report

New report and event examine the new era of vaccines

PhRMA  |  Blog Post

Our 2017 Medicines in Development: Vaccines update, released today, highlights the more than 260 vaccines in development to treat and prevent disease.
http://catalyst.phrma.org/new-report-and-event-examine-the-new-era-of-vaccines

ICYMI: New report outlines steps for greater transparency in health care

PhRMA  |  Blog Post

Read the full NEHI report here. 
http://catalyst.phrma.org/icymi-new-report-outlines-steps-for-greater-transparency-in-health-care

Medicines in Development for Neurological Disorders 2015 Report

PhRMA  |  Report

Learn more in the Medicines in Development report
https://www.phrma.org/report/medicines-in-development-for-neurological-disorders-2015-report

Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

PhRMA  |  Blog Post

We view the report as a potential basis for engaging trading partners to more effectively address negative practices and regain a level-playing field for American companies – particularly those that rely heavily on IP protections like companies in the innovative biopharmaceutical industry.
http://catalyst.phrma.org/administrations-special-301-report-highlights-deteriorating-global-environment-for-biopharmaceutical-innovation

New report shows better diabetes management saves money and improves patient outcomes

PhRMA  |  Blog Post

According to the report, better management of diabetes in the Medicaid program could: Reduce the national average onset of hypertension, ischemic heart disease, heart attack and stroke by between 13 to 28 percent over the next 10 years for adult enrollees with diabetes Reduce the national average onset of these health issues by between 18 to 34 percent for adult enrollees with uncontrolled diabetes Disease Onset Reduction Over the Next Ten Years   The study’s results highlight the substantial positive impact that improved medication adherence could have for the health care system and the more than 30 million Americans affected by diabetes.
http://catalyst.phrma.org/new-report-shows-better-diabetes-management-saves-money-and-improves-patient-outcomes

Medicines in Development for HIV 2017 Report

PhRMA  |  Report

Since the human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS), was first identified in the United States more than 30 years ago, expanded treatment options have brought down death rates, increased patient adherence, improv...
https://www.phrma.org/report/medicines-in-development-for-hiv-2017-report

PhRMA Statement on Report President Commissions’ Final Report with Opioid Recommendations

PhRMA  |  Press Release

WASHINGTON, D.C. (November 2, 2017) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement: “Solving the current opioid crisis requires a comprehensive approach that ba...
https://www.phrma.org/press-release/phrma-statement-on-report-president-commissions-final-report-with-opioid-recommendations

Medicines in Development for Alzheimer's Disease 2017 Report

PhRMA  |  Report

America’s biopharmaceutical research companies are investigating or developing 85 medicines to help the more than 5 million patients in the United States who are living with Alzheimer’s disease. The medicines in development are all in either clinical trials or under review by the Food and Drug Ad...
https://www.phrma.org

4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report

PhRMA  |  Blog Post

Here are four things you should know about the latest QuintilesIMS report: Prices for existing brand-name medicines declined by an average of 2.5 percent annually over the last six years, primarily due to patent expirations and generic competition.
http://catalyst.phrma.org/4-things-to-know-about-the-quintilesims-drivers-of-medicine-spending-in-the-u.s.-report

ICYMI: Report highlights overall decrease in cancer death rates

PhRMA  |  Blog Post

When comparing data from 1975 to 1977 and 2006 to 2012, the report found the five-year survival rates for some distant-stage types of cancer increased significantly.
http://catalyst.phrma.org/icymi-report-highlights-overall-decrease-in-cancer-death-rates

Medicines in Development for Arthritis 2014 Report

PhRMA  |  Report

Approximately 15 million adults report that they are unable to perform some common activities due to the pain; 10 for osteoarthritis, the most com-mon form of arthritis, which affects nearly 27 million Americans; and 7 for psoriatic arthritis, an in?
https://www.phrma.org/report/medicines-in-development-for-arthritis-2014-report

Medicines in Development for COPD 2012 Report

PhRMA  |  Report

“The promising new therapies highlighted in this report illustrate how emerging scientific approaches, to treating respiratory diseases such as COPD, offer great hope to improve and save the lives of future patients.”
https://www.phrma.org/report/medicines-in-development-for-copd-report

ICYMI Report highlights increasing prevalence for Alzheimer's disease

PhRMA  |  Blog Post

Biopharmaceutical researchers however remain committed to finding treatments for Alzheimer’s and are currently researching 85 potential medicines.
http://catalyst.phrma.org/icymi-report-highlights-increasing-prevalence-for-alzheimers-disease

You have reviewed the first 25 results out of 1032. Each page contains 25 results. You're on page 1.

prev 1 2 3 4 5 6 next